Your session is about to expire
← Back to Search
Topoisomerase I inhibitors
LMP744 for Lymphoma
Phase 1
Waitlist Available
Led By Alice P Chen, M.D.
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must have histologically documented metastatic solid tumors which have progressed after one line of therapy, or lymphoma which has progressed after initial therapy and without potentially curative options, or patient refuses potentially curative therapy.
Patients must have measurable or evaluable disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cycle 1
Awards & highlights
Study Summary
This trial is testing the safety of a new drug, LMP744, which damages DNA and causes cell death, in order to see if it can treat certain kinds of cancer. Researchers will be testing the safety of the drug and what dose of the drug can be safely given to humans.
Eligible Conditions
- Lymphoma
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You have advanced cancer that has spread to other parts of your body and has not responded to initial treatment.
Select...
You have a condition that can be measured or evaluated by the doctors.
Select...
You can have received treatment with topoisomerase I inhibitors in the past.
Select...
You can participate in this therapy if you are not currently taking denosumab or bisphosphonates for any type of cancer, or if you are not undergoing hormone therapy for prostate cancer.
Select...
You are willing to give blood and tumor samples for research if you are in the later part of the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ cycle 1
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cycle 1
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To establish the safety, tolerability and the maximum tolerated dose (MTD) of LMP744 (NSC 706744)
Secondary outcome measures
Pyruvate Kinase
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
LMP744 will be administered IV over 1 hour on days 1-5 of each 28-day cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LMP744
2017
Completed Phase 1
~40
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
13,658 Previous Clinical Trials
40,924,605 Total Patients Enrolled
1,381 Trials studying Lymphoma
382,365 Patients Enrolled for Lymphoma
Alice P Chen, M.D.Principal InvestigatorNational Cancer Institute (NCI)
16 Previous Clinical Trials
3,632 Total Patients Enrolled
5 Trials studying Lymphoma
3,186 Patients Enrolled for Lymphoma
Geraldine H O'Sullivan Coyne, M.D.Principal InvestigatorNational Cancer Institute (NCI)
2 Previous Clinical Trials
67 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You can have received treatment with topoisomerase I inhibitors in the past.You have advanced cancer that has spread to other parts of your body and has not responded to initial treatment.You have a condition that can be measured or evaluated by the doctors.You are not currently taking any other experimental drugs.You can participate in this therapy if you are not currently taking denosumab or bisphosphonates for any type of cancer, or if you are not undergoing hormone therapy for prostate cancer.You are willing to give blood and tumor samples for research if you are in the later part of the study.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What are the odds of experiencing negative side effects from LMP744?
"LMP744's safety is estimated to be a 1 because it is a Phase 1 trial, meaning that there is only initial data supporting safety and efficacy."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger